

Table S6 - Utilities derived for skin disease

Author, Year, Country	Study Design	Condition	Interventions	Setting	Mean (SD) Age	% Males	Utility Instrument	Baseline Utility		End of Study Utility	
								N	Mean (SD)	N	Mean (SD)
Children/Adolescents & Adults											
Klassen et al. 2000 England	Non-randomized, prospective; 12 months	Acne	Isotretinoin or antibiotic, hormonal, physical or topical treatments	Dermatology clinic	22.1 (5.2)	61.3	EQ-5D index	54	0.84 (0.17)	54	0.93 (0.15)
Mittmann et al. 1999 Canada	Cross-sectional	Acne	n/a	National health survey (n=17,626)	n/a (age≥12)	45.7	HUI 3	Overall: 476 Age 12-19: 85 Age 20-29: 48	0.92 (0.09) 0.92 (0.90) 0.92 (0.09)	n/a	n/a
Children/Adolescents											
Stevens et al. 2005 Germany	Cross-sectional; adults surveyed about children's preferences	Atopic dermatitis	n/a	General population survey	54	40.1	SG	137	0.841	n/a	n/a
Chen et al. 2008 USA	Cross-sectional	Acne	n/a	Four high schools	15.4 (1.3)	41	TTO	265	0.961 (0.092)	n/a	n/a
Adult											
Bergstrom et al. 2003 USA	RCT, 14 days	Psoriasis ≥ 3% of body surface area	Clobetasol propionate: foam vs combined cream & solution	Clinic	49	79	EQ-5D index	n/a	n/a	29	Foam: change -0.71 Cream/solution: change -0.13
Revicki et al. 2008 8 in Europe + Canada	RCT, 16 weeks	Moderate to severe plaque psoriasis	Adalimumab; MTX; placebo	28 centres	Placebo: 40.7 (11.4) MTX: 41.9 (11.9) Adalimumab: 42.8 (12.3)	66 67 64	EQ-5D index	53 108 103	Placebo: 0.7 (0.3) MTX: 0.7 (0.2) Adalimumab: 0.7 (0.3)	53 108 103	Placebo: 0.8 (0.3) MTX: 0.9 (0.2) Adalimumab: 0.9 (0.1)
Shikiar et al. 2007 USA & Canada	Phase II RCT, 12 weeks	Moderate to severe plaque psoriasis	Adalimumab (weekly or EOW) vs placebo	18 centres	Placebo: 43 Adalimumab EOW: 46 Adalimumab Weekly: 44	65 71 66	EQ-5D index	52 45 50	Placebo: 0.67 Adalimumab EOW: 0.69 Adalimumab Weekly: 0.69	52 45 50	Placebo: 0.68 Adalimumab EOW: 0.89 Adalimumab Weekly: 0.86
Shikiar et al. 2006 USA & Canada	RCT, 12 weeks	Moderate to severe plaque psoriasis	Adalimumab vs placebo	Multicentre	44.2 (12.7)	67.3	EQ-5D index	147	0.66 (0.28)	140	0.82 (0.23)
Stratton et al. 2001 UK	Non-randomized, prospective, pilot study, 12 months	Scleroderma	Anti-human lymphocyte globulin plus mycophenolate mofetil	Connective tissue diseases unit	Median: 52	26	EQ-5D index	13	0.54 (0.073)	13	0.49 (0.076)
Saarni et al. 2006 Finland	Cross-sectional	Psoriasis	n/a	General population survey (n=6681)	52.6	47	EQ-5D index	Psoriasis: 2.3% of population	0.796 (0.019)	n/a	n/a
Weiss et al. 2002 USA	Cross-sectional study of patients enrolled in RCT	Moderate to severe psoriasis	n/a	NIH clinical centre	49	60	EQ-5D index	35	0.724	n/a	n/a
Littenberg et al. 2003 USA	Longitudinal cohort test-retest reliability; 1-2 weeks	Stable skin disease	None	Postal questionnaire and dermatology clinic	51.9	24.3	SG	Overall: 74 Acne: 6 Keratosis: 16 Nevus: 6 Psoriasis: 5	0.9776 0.999 0.989 0.975 0.925	74	0.9779
Lundberg et al. 1999 Sweden	Cohort	Psoriasis; atopic eczema	None	Dermatology outpatient clinic	Psoriasis: 49.9 (13.1) Eczema: 34.8 (12.0)	51 29	SG	Psoriasis only: 77 Psoriasis total: 234 Atopic eczema only: 34 Eczema total: 132	0.99 (0.044) 0.97 (0.107) 1.00 (0.102) 0.98 (0.069)	n/a	n/a
							TTO	Psoriasis only: 77 Psoriasis total: 234 Atopic eczema only: 34 Eczema total: 132	0.93 (0.132) 0.88 (0.153) 0.95 (0.128) 0.93 (0.115)	n/a	n/a
Khanna et al. 2007 USA	Cross-sectional	Systemic sclerosis	n/a	Conference attendees	54.4 (12.7)	9.4	SG	107	0.76 (0.28)	n/a	n/a
							TTO	107	0.76 (0.25)	n/a	n/a

Zug et al. 1995 USA	Cross-sectional	Psoriasis	n/a	Dermatology clinic	Median: 49	54	SG	Psoriasis: 82 covers <10% of skin covers 10-30% of skin covers >30% of skin	0.82 0.78 0.62	n/a	n/a
							TTO	Psoriasis: 82 covers <10% of skin covers 10-30% of skin covers >30% of skin	0.89 0.79 0.59		
Chen et al. 2004 USA	Cross-sectional	Psoriasis; dermatitis; acne	n/a	Hospital (n=250)	46 (17)	43	TTO	Psoriasis: 11 Acne: 28 Atopic dermatitis: 5 Contact dermatitis: 10 Eczema and xerosis: 11 Lichen simplex chronicus: 5 20	0.907 (0.121) 0.938 (0.124) 0.890 (0.134) 0.898 (0.159) 0.968 (0.055) 0.987 (0.022) 0.95	n/a	n/a
Schiffner et al. 2002 Germany	Cross-sectional	Port wine stains on the face	n/a	Survey of patients who had completed laser therapy (n=25)	42	52	TTO			n/a	n/a
Schiffner et al. 2003 Germany	Pre-post design, prospective; 12 weeks	Psoriasis	Balneo-phototherapy	Physican	43.9	60.9	TTO	138	0.888	134	0.904
Schmitt et al. 2008 Germany	Cross-sectional	Psoriasis; atopic eczema	n/a	Community	Psoriasis: 49.8 Eczema: 27.8	62.1 27.4	TTO	<u>Psoriasis</u> : 58 controlled uncontrolled <u>Eczema</u> : 62 controlled uncontrolled	0.88 0.45 0.96 0.65	n/a	n/a

SD-standard deviation; n/a-not available; RCT-randomized controlled trial